Boehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed to strengthen the country’s domestic pharma infrastructure.
NICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a treatment for a kind of advanced lung cancer, citing “highly uncertain” data about the d